Analysis Shows Biosimilars Lower Patient Costs
While biosimilars are known to reduce healthcare costs overall, many patients want to know exactly how much biosimilars can save them in out-of-pocket spending. A recent analysis presented at the Academy of Managed Care Pharmacy in October 2018 compared patient out of pocket responsibility for Zarxio® (filgrastim-sndz) and Neupogen® (filgrastim). The analysis found that patient costs were approximately 9% lower for the biosimilar than for the original biologic. This could result in a savings of more than $8 million for Medicare beneficiaries nationwide.